PX1 Research provides USA-manufactured, high-purity Tesamorelin and Ipamorelin compounds synthesized for rigorous in vitro and preclinical investigation. Designed for laboratories evaluating dual-pathway growth hormone secretagogue activity, each batch undergoes independent HPLC/MS purity verification and endotoxin testing. Place your order before 3 PM EST for same-day dispatch from our California or Arizona facilities.
PX1 Research provides USA-manufactured, high-purity Tesamorelin and Ipamorelin compounds synthesized for rigorous in vitro and preclinical investigation. Designed for laboratories evaluating dual-pathway growth hormone secretagogue activity, each batch undergoes independent HPLC/MS purity verification and endotoxin testing. Place your order before 3 PM EST for same-day dispatch from our California or Arizona facilities.
To buy Tesamorelin and Ipamorelin for laboratory research, select a domestic supplier offering lot-specific HPLC/MS purity analysis and endotoxin testing. PX1 Research synthesizes both growth hormone secretagogues in GMP-compliant USA facilities, providing sequence-verified research compounds with guaranteed ≥99% purity and full batch traceability for in vitro and preclinical research applications.
Investigators interested in the somatotrophic axis frequently evaluate Tesamorelin and Ipamorelin to observe dual-pathway growth hormone stimulation. When sourcing these compounds, ensuring absolute sequence integrity and freedom from synthesis-byproduct contaminants is critical for maintaining experimental reproducibility across cellular assays and animal models.
Tesamorelin is a synthetic N-terminally modified analog of human Growth Hormone-Releasing Hormone (GHRH), consisting of a 44-amino acid sequence attached to a trans-3-hexenoyl group. This lipophilic modification increases plasma stability relative to native endogenous GHRH. Preclinical models demonstrate that Tesamorelin selectively binds to the GHRH receptor (GHRHR) on pituitary somatotrophs, triggering adenylate cyclase activation and subsequent intracellular cyclic AMP (cAMP) accumulation to stimulate growth hormone synthesis and release.
In contrast, Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belonging to the growth hormone secretagogue receptor (GHSR-1a) agonist class, often referred to as ghrelin mimetics. In vitro receptor binding assays demonstrate that Ipamorelin binds selectively to GHSR-1a, activating phospholipase C and the inositol triphosphate (IP3) signaling cascade. By targeting distinct receptors on the somatotroph membrane, these two research peptides engage orthogonal secondary messenger pathways within the cell.
When evaluated in combined preclinical protocols, GHRH agonists and GHSR-1a agonists exhibit complementary, synergistic activity on pituitary somatotrophs. In vitro perifusion studies demonstrate that simultaneous activation of GHRHR (via cAMP generation) and GHSR-1a (via intracellular calcium mobilization) produces a significantly greater release of growth hormone than the mathematical sum of either agent tested individually.
Furthermore, preclinical research indicates that co-investigation of these pathways avoids early desensitization of the somatotroph apparatus. Because Ipamorelin does not compete for the GHRH receptor site, the endogenous pulsatile nature of growth hormone expression is maintained in rodent models without triggering premature receptor downregulation or exhaustion of somatotrophic vesicles.
A primary focus of growth hormone secretagogues research is target selectivity—specifically, the activation of GH release without confounding elevations in non-target pituitary hormones. Early-generation secretagogues frequently triggered unselected depolarizations, resulting in transient surges of adrenocorticotropic hormone (ACTH), cortisol, and prolactin.
Preclinical data indicate that Ipamorelin demonstrates exceptional receptor selectivity. In canine and rodent models, administration of Ipamorelin across a wide dose range did not cause statistically significant elevations in plasma cortisol or prolactin. Similarly, in vitro assays using Tesamorelin confirm that GHRHR binding remains strictly specific to the GH pathway, rendering this dual-compound model ideal for isolating somatotrophic mechanisms without metabolic confounding factors.
High-purity reagents are essential when conducting cellular cross-talk experiments or receptor binding kinetics. Impurities such as truncated peptide sequences, deletion sequences, or residual TFA (trifluoroacetic acid) can bind non-specifically to membrane receptors, distorting EC50 calculations and downstream signaling data.
At PX1 Research, every batch of Tesamorelin and Ipamorelin undergoes rigorous analytical validation before distribution. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) confirms chemical purity exceeding 99%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular weight and sequence fidelity. Furthermore, chromogenic Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin levels below <0.01 EU/mg, protecting primary cell cultures from inflammatory artifacts.
To properly contextualize these compounds within the broader family of secretagogues, researchers frequently compare their signaling kinetics against other established agents in our peptide research library. The table and comparison below highlight structural and functional distinctions across the somatotrophic axis.
When comparing Tesamorelin and Ipamorelin to legacy GHRH analogs like Sermorelin, long-acting constructs like CJC-1295 DAC, or first-generation ghrelin agonists like GHRP-6, notable differences emerge in receptor half-life and selectivity. While CJC-1295 DAC exhibits prolonged binding via albumin conjugation, Tesamorelin maintains a natural pulsatile clearance profile. Meanwhile, Ipamorelin lacks the non-selective ghrelin-mediated appetite stimulation and cortisol release associated with GHRP-6.
Proper handling and reconstitution protocols are vital to preserve the tertiary structure and bioactivity of lyophilized peptide powders. Upon receiving research-grade Tesamorelin or Ipamorelin, vials should be allowed to equilibrate to room temperature inside a laminar flow hood before reconstitution to prevent atmospheric condensation.
Reconstitution should be performed using sterile, laboratory-grade Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Deionized Water, depending on the requirements of your specific assay. Liquid diluent should be introduced gently down the inner glass wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirly agitation—never vigorous vortexing—should be applied until complete dissolution occurs to avoid mechanical shearing of the peptide chains.
Lyophilized research compounds from PX1 Research are stable at ambient room temperatures during short-term transit. However, upon arrival at the research facility, un-reconstituted vials must be stored in a sub-zero environment (-20°C to -80°C) protected from direct light exposure for long-term storage integrity.
Once reconstituted into aqueous solution, peptide stability decreases over time due to hydrolytic degradation pathways. Aliquoting reconstituted solutions into single-use microcentrifuge tubes reduces freeze-thaw degradation cycles. Reconstituted aliquots stored at 2°C to 8°C should generally be utilized within 14 to 30 days, while frozen aliquots stored at -20°C maintain structural stability for extended preclinical study timelines.
Selecting a domestic, USA-manufactured supplier eliminates common risks associated with overseas procurement, including customs seizures, batch inconsistency, unidentified heavy metals, and degradation due to prolonged, uncontrolled ambient transit. PX1 Research operates under strict quality management frameworks within ISO 17025 accredited analytical environments.
We support institutional procurement, university laboratories, and private research entities requiring consistent supply chain reliability. Organizations seeking bulk quantities for high-throughput screening projects can submit inquiries directly through our wholesale peptide portal. All orders placed Monday through Friday prior to 3 PM EST are processed and shipped same-day from our dual California and Arizona fulfillment centers.
What receptor pathways do Tesamorelin and Ipamorelin target?
Tesamorelin selectively targets the Growth Hormone-Releasing Hormone Receptor (GHRHR), stimulating adenylate cyclase and cAMP pathways. Ipamorelin selectively targets the Growth Hormone Secretagogue Receptor (GHSR-1a), mobilizing intracellular calcium via phospholipase C.
How does PX1 Research verify the purity of Tesamorelin and Ipamorelin?
Every lot undergoes independent third-party analysis using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity quantification (≥99%) and Electrospray Ionization Mass Spectrometry (ESI-MS) for structural identity verification. COAs are publicly accessible per batch.
Are Tesamorelin and Ipamorelin tested for bacterial endotoxins?
Yes. Every production lot undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels are strictly below <0.01 EU/mg, ensuring suitability for sensitive cell cultures and animal models.
Why are Tesamorelin and Ipamorelin evaluated together in preclinical research?
Preclinical models demonstrate synergistic growth hormone release when GHRHR and GHSR-1a are stimulated simultaneously. Combining these distinct pathways yields a higher somatotroph response than activating either receptor alone.
What solvent is recommended for reconstituting lyophilized peptide vials?
Sterile Bacteriostatic Water (0.9% benzyl alcohol) is standard for multi-use research sampling, while Sterile Normal Saline or Deionized Water may be used for immediate in vitro cell assays sensitive to preservatives.
Does Ipamorelin stimulate cortisol or prolactin release in experimental models?
In preclinical and animal study models, Ipamorelin has demonstrated high receptor selectivity, producing no statistically significant elevation in plasma cortisol, ACTH, or prolactin levels.
How should reconstituted Tesamorelin and Ipamorelin solutions be stored?
Reconstituted liquid solutions should be stored at 2°C to 8°C and used within 14–30 days. For longer storage, single-use aliquots should be frozen at -20°C to minimize freeze-thaw degradation cycles.
Where are PX1 Research peptides synthesized and shipped from?
All PX1 Research compounds are USA-manufactured in GMP-compliant facilities and dispatched same-day (M–F before 3 PM EST) from our CA and AZ logistics hubs.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.